Volume | 2,246,896 |
|
|||||
News | - | ||||||
Day High | 108.19 | Low High |
|||||
Day Low | 105.25 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Moderna Inc | MRNA | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
106.18 | 105.25 | 108.19 | 107.97 | 106.18 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
36,289 | 2,246,896 | $ 107.44 | $ 241,413,202 | - | 62.55 - 142.79 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
19:33:25 | 20 | $ 107.51 | USD |
Moderna (MRNA) Options Flow Summary
Moderna Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
41.25B | 382.07M | - | 6.85B | -4.71B | -12.34 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Moderna News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical MRNA Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 102.37 | 111.29 | 99.30 | 105.84 | 2,880,696 | 6.11 | 5.97% |
1 Month | 106.40 | 115.89 | 97.00 | 105.65 | 3,054,556 | 2.08 | 1.95% |
3 Months | 97.39 | 115.89 | 84.06 | 100.65 | 3,819,698 | 11.09 | 11.39% |
6 Months | 76.73 | 115.97 | 62.55 | 93.71 | 4,427,572 | 31.75 | 41.38% |
1 Year | 134.67 | 142.79 | 62.55 | 102.53 | 4,043,597 | -26.19 | -19.45% |
3 Years | 171.79 | 497.17 | 62.55 | 219.63 | 6,998,869 | -63.31 | -36.85% |
5 Years | 25.83 | 497.17 | 11.54 | 147.51 | 8,829,842 | 82.65 | 319.98% |
Moderna Description
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its COVID-19 vaccine, which was authorized in the United States in December 2020. Moderna had 44 mRNA development programs as of early 2022, with 25 of these in clinical trials. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases. |